Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V, Palladini G, Minnema MC, Jaccard A, Lee HC, Gibbs S, Mollee P, Venner C, Lu J, Schönland S, Gatt M, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Chauveau D, Gries KS, Fastenau J, Tran NP, Qin X, Vasey SY, Weiss BM, Vermeulen J, Ho KF, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD. Sanchorawala V, et al. Among authors: bumma n. Am J Hematol. 2022 Jun 1;97(6):719-730. doi: 10.1002/ajh.26536. Epub 2022 Mar 30. Am J Hematol. 2022. PMID: 35293006 Free article. Clinical Trial.
Daratumumab proves safe and highly effective in AL amyloidosis.
Khouri J, Kin A, Thapa B, Reu FJ, Bumma N, Samaras CJ, Liu HD, Karam MA, Reed J, Mathur S, Faiman BM, Devries G, Zonder J, Valent J. Khouri J, et al. Among authors: bumma n. Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25. Br J Haematol. 2019. PMID: 29938774 Free article. No abstract available.
Potential of NK cells in multiple Myeloma therapy.
Khan AM, Devarakonda S, Bumma N, Chaudhry M, Benson DM Jr. Khan AM, et al. Among authors: bumma n. Expert Rev Hematol. 2019 Jun;12(6):425-435. doi: 10.1080/17474086.2019.1617128. Epub 2019 May 22. Expert Rev Hematol. 2019. PMID: 31070067
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Palladini G, et al. Among authors: bumma n. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460. Blood. 2020. PMID: 32244252 Free PMC article. Clinical Trial.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. Among authors: bumma n. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
Ozga M, Zhao Q, Benson D Jr, Elder P, Williams N, Bumma N, Rosko A, Chaudhry M, Khan A, Devarakonda S, Kahwash R, Vallakati A, Campbell C, Parikh SV, Almaani S, Prosek J, Bittengle J, Pfund K, LoRusso S, Freimer M, Redder E, Efebera Y, Sharma N. Ozga M, et al. Among authors: bumma n. Cancer Med. 2021 Feb;10(3):965-973. doi: 10.1002/cam4.3683. Epub 2020 Dec 21. Cancer Med. 2021. PMID: 33347707 Free PMC article.
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.
Sharma N, Chen DT, Zhao Q, Williams NY, Rosko A, Benson DM, Chaudhry M, Bumma N, Khan A, Devarakonda S, Hofmeister CC, Sborov D, Efebera YA. Sharma N, et al. Among authors: bumma n. Biol Blood Marrow Transplant. 2020 Jan;26(1):44-49. doi: 10.1016/j.bbmt.2019.09.005. Epub 2019 Sep 10. Biol Blood Marrow Transplant. 2020. PMID: 31518644 Free article. Clinical Trial.
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Pasvolsky O, et al. Among authors: bumma n. Bone Marrow Transplant. 2022 Jan;57(1):31-37. doi: 10.1038/s41409-021-01455-y. Epub 2021 Oct 4. Bone Marrow Transplant. 2022. PMID: 34608275 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36164142
42 results